Ads
related to: il 6 antibody tocilizumab results meaning list- Downloadable Resources
Get Resources For You
And Your Patients Today
- Treatment Savings
As Little As $0 Copay Per Month.
Subject to Terms and Conditions
- Supporting Patients
Find Support For Your Patients.
Learn More Today
- Specialty Pharmacies
Learn More About
In-Network Specialty Pharmacies
- Downloadable Resources
Search results
Results From The WOW.Com Content Network
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. In humans, it is encoded by the IL6 gene. [5] In addition, osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer.
A TNF-α (tumor necrosis factor-alpha) binding protein is a monoclonal antibody or a circulating receptor such as infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira) that binds to TNF-α, preventing it from inducing the synthesis of IL-1 and IL-6 and the adhesion of lymphocyte-activating molecules.
Ad
related to: il 6 antibody tocilizumab results meaning list